1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Hepatitis

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C

Technology appraisal guidance [TA75] Published date: 28 January 2004 Last updated: 01 November 2013

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Recommendations for further research
  • 6 Implications for the NHS
  • 7 Implementation and audit
  • 8 Related guidance
  • 9 Review of guidance
  • Appendix A. Appraisal Committee members and NICE project team
  • Appendix B. Sources of evidence considered by the Committee
  • Appendix C. Detail on criteria for audit of the use of interferon alfa (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C
  • Changes after publication
  • About this guidance
Download guidance (PDF)

Guidance

  • Next

Changes after publication

Changes after publication

November 2013: This guidance has been partially updated by 'Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people' (NICE technology appraisal guidance 300).

March 2012: minor maintenance.

September 2010: This guidance has been partially updated by 'Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C' (NICE technology appraisal guidance 200).


  • Next